Uveal Melanoma – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Uveal Melanoma – Pipeline Review, H1 2017’, provides an overview of the Uveal Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Uveal Melanoma

The report reviews pipeline therapeutics for Uveal Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Uveal Melanoma therapeutics and enlists all their major and minor projects

The report assesses Uveal Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Uveal Melanoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Uveal Melanoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Uveal Melanoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bellicum Pharmaceuticals Inc

Bristol-Myers Squibb Company

Celldex Therapeutics Inc

Cleveland BioLabs Inc

Delcath Systems Inc

Eli Lilly and Company

Iconic Therapeutics Inc

Immunocore Ltd

Lion Biotechnologies Inc

Navigen Inc

Novartis AG

PEP-Therapy SAS

Pfizer Inc

Polaris Pharmaceuticals Inc

Spectrum Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Uveal Melanoma - Overview

Uveal Melanoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Uveal Melanoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Uveal Melanoma - Companies Involved in Therapeutics Development

Bellicum Pharmaceuticals Inc

Bristol-Myers Squibb Company

Celldex Therapeutics Inc

Cleveland BioLabs Inc

Delcath Systems Inc

Eli Lilly and Company

Iconic Therapeutics Inc

Immunocore Ltd

Lion Biotechnologies Inc

Navigen Inc

Novartis AG

PEP-Therapy SAS

Pfizer Inc

Polaris Pharmaceuticals Inc

Spectrum Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Uveal Melanoma - Drug Profiles

AU-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPX-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Metastatic Uveal Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crizotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emibetuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entolimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glembatumumab vedotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hI-con1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HPH-196 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HPH-211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMCgp-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ipilimumab + nivolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KCN-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LXS-196 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melphalan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

merestinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAV-2729 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nutlin-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegargiminase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEP-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sotrastaurin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sunitinib malate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vincristine sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Uveal Melanoma - Dormant Projects

Uveal Melanoma - Discontinued Products

Uveal Melanoma - Product Development Milestones

Featured News & Press Releases

Nov 09, 2016: Immunocore Presents Positive Monotherapy Data in Uveal Melanoma at the Society for Melanoma Research (SMR) 2016 Congress

Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016

Mar 30, 2016: Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma

Jan 25, 2016: Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma

Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC

Sep 09, 2015: Immunocore’s IMCgp100 Accepted for Adaptive Pathway Pilot Programme

Jun 29, 2015: Lilly and Immunocore To Conduct Phase Ib/II Clinical Trial Collaboration For Treatment Of uveal melanoma

May 22, 2015: Additional Tumor Type Cohorts Added to the Ongoing Phase 1 Study Combining ADI-PEG 20 with Cisplatin and Pemetrexed Based on New Research Results

May 21, 2015: FDA Grants Orphan Drug Designation to Aura Biosciences’ Novel Treatment for Uveal Melanoma

Apr 14, 2015: Navigen Announces Phase I SBIR Award to Support Development of Uveal Melanoma Therapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Uveal Melanoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Uveal Melanoma – Pipeline by Bellicum Pharmaceuticals Inc, H1 2017

Uveal Melanoma – Pipeline by Bristol-Myers Squibb Company, H1 2017

Uveal Melanoma – Pipeline by Celldex Therapeutics Inc, H1 2017

Uveal Melanoma – Pipeline by Cleveland BioLabs Inc, H1 2017

Uveal Melanoma – Pipeline by Delcath Systems Inc, H1 2017

Uveal Melanoma – Pipeline by Eli Lilly and Company, H1 2017

Uveal Melanoma – Pipeline by Iconic Therapeutics Inc, H1 2017

Uveal Melanoma – Pipeline by Immunocore Ltd, H1 2017

Uveal Melanoma – Pipeline by Lion Biotechnologies Inc, H1 2017

Uveal Melanoma – Pipeline by Navigen Inc, H1 2017

Uveal Melanoma – Pipeline by Novartis AG, H1 2017

Uveal Melanoma – Pipeline by PEP-Therapy SAS, H1 2017

Uveal Melanoma – Pipeline by Pfizer Inc, H1 2017

Uveal Melanoma – Pipeline by Polaris Pharmaceuticals Inc, H1 2017

Uveal Melanoma – Pipeline by Spectrum Pharmaceuticals Inc, H1 2017

Uveal Melanoma – Pipeline by Syndax Pharmaceuticals Inc, H1 2017

Uveal Melanoma – Dormant Projects, H1 2017

Uveal Melanoma – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Uveal Melanoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports